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ABSTRACT: Saponins are potential wide-spectrum antitu-
mor drugs, and copper(I) catalyzed azide−alkyne 1,3-dipolar
cycloaddition is a suitable approach to synthesizing saponin-
like compounds by regioselective glycosylation of the C2/C3
hydroxyl and C28 carboxylic groups of triterpene aglycones
maslinic acid (MA) and oleanolic acid (OA). Biological
studies on the T-84 human colon carcinoma cell line support
the role of the hydroxyl groups at C2/C3, the influence of the
aglycone, and the bulky nature of the substituents in C28. OA
bearing a α-D-mannose moiety at C28 (compound 18)
focused our interest because the estimated inhibitory concentration 50 was similar to that reported for ginsenoside Rh2 against
colon cancer cells and it inhibits the G1−S phase transition affecting the cell viability and apoptosis. Considering that
triterpenoids from natural sources have been identified as inhibitors of nuclear factor kappa-light-chain-enhancer of activated B
cell (NF-κB) signaling, docking studies were conducted to evaluate whether NF-κB may be a potential target. Results are
consistent with the biological study and predict a similar binding mode of MA and compound 18 to the p52 subunit from NF-
κB but not for OA. The fact that the binding site is shared by the NF-κB inhibitor 6,6-dimethyl-2-(phenylimino)-6,7-
dihydrobenzo[d][1,3]oxathiol-4(5H)-one supports the result and points to NF-κB as a potential target of both MA and
compound 18.
■ INTRODUCTION
Cancer is the second cause of death and morbidity in
developed countries. According to the World Health
Organization, about 8.8 million people worldwide died from
cancer in 2015, which represents nearly one in six of all global
death and an estimated economic cost of $1.16 trillion.1
Distribution of cancer is associated with socioeconomic
development, the countries with a high human development
index (HDI) being responsible for 41% of the cases, whereas
low-HDI countries for only less than 6%. Despite this fact, the
transition of low-income countries to higher development will
have profound effects on the scale and profile of the cancer.2
Among the different cancers, colorectal cancer shows a strong
correlation with lifestyle, and it can be considered as a marker
of developmental transition and adoption of a western
lifestyle.2,3 This is one of the three most common cancers
expected in United States and is rising rapidly in low-income
and middle-income countries.3,4
Saponins are secondary metabolites that are gaining
increasing attention as potential wide-spectrum antitumor
drugs because apart from provoking membrane permeabiliza-
tion when administrated at high concentrations, at low
concentrations, they show cytostatic, proapoptotic, and
antimetastatic effects on tumor cells.5,6 From a chemical
point of view, saponins consist of a nonpolar polycyclic part,
referred to as aglycone or sapogenin, attached to one or more
sugar side chains (i.e., glycone). On the basis of the chemical
character of the aglycone and the number of directly bound
sugar chains, saponins are divided into steroidal and
triterpenoid saponins and categorized into monodesmosides
(one chain), bisdesmosides (two chains), or trisdesmosides
(three chains). Naturally occurring triterpenoid saponins
mainly contain aglycones with 30 carbon atoms, the most
commonly core structures being pentacyclic oleananes and
tetracyclic dammaranes, and their antitumor activity has been
proven.6,7 The degree of structural diversity and the fact that
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minor structural changes in the molecules may lead to a major
difference in activity make the prediction of the biological
activity from the structure−activity relationship a real
challenge. Additionally, the isolation of saponins from plant
material is difficult and time-consuming and the synthesis on
industrial scale is far from trivial.8 In this context, β-hederin
(oleanolic acid 3-O-α-L-rhamnopyranosyl-(1 → 2)-α-L-arabi-
nopyranoside) has been a source of inspiration to synthesize
different families of new active compounds.9,10
Interestingly, pentacyclic triterpenes present in the skin of
the fruit of Olea europaea have been proposed to have a
positive effect on colon tumors and, among them, maslinic acid
(2α,3β-dihydroxyolean-12-ene-28-oic) (MA) and oleanolic
acid (3β-hydroxyolean-12-ene-28-oic) (OA) stand out.11−15
The bioactivity of these triterpenes is not limited to antitumor
activity but includes cardioprotective, anti-inflammatory,
antioxidative, antileukemic, antithrombotic, antidiabetic, anti-
hypertensive, antihyperlipidemic, immunomodulating, antivi-
ral, antibacterial, and antiprotozoal activities.16−18 The low
toxicity and the broad bioactivity spectrum of MA and OA
make them attractive compounds for chemical modifications to
improve the potency, selectivity, and/or pharmacokinetic
parameters.18 Thus, OA and, to a lesser extent, MA have
been modified in three “active portions”: the hydroxyl groups
at C2 and/or C3, the C12−C13 double bond, and the C28
carboxylic group, many of the resulting molecules showing
improved antitumor activity.19−25 However, the poor water
solubility of triterpenoids is a key factor that limits their clinical
application as therapeutic agents and PEGylation and
glycosylation have been demonstrated to be successful
strategies that improve water solubility and preserve the
biological activity.26−28
Pentacyclic triterpenes and triterponoid saponins probably
act at multiple levels although the target molecules are still
being identified. Cumulative experimental and epidemiologic
lines of evidence suggest a link between inflammation and
cancer, and recent studies have demonstrated the relevance of
chronic inflammation in colorectal cancer development.29 Of
particular importance is the function of pro- and anti-
inflammatory cytokines. Among them, the tumor necrosis
factor activates nuclear factor kappa-light-chain-enhancer of
activated B cell (NF-κB), inducing the expression of various
genes that stimulate tumor-associated inflammation, including
cyclooxygenase-2 (COX-2).29 In this context, the fact that
triterpenoids from natural sources such as ginsenosides,
glycyrrhizin, betulin, lupeol, and avicins have been identified
as inhibitors of NF-κB signaling may be one of the keys to
understand their effect at cellular level.30 This observation is
especially relevant when taking into account that aberrant NF-
κB regulation has been observed in many cancers, including
colon, lung, breast, and prostate, that are the main contributors
to the statistics of cancer worldwide, and the inhibition of NF-
κB has been identified as a promising option to improve
anticancer therapy.31−33
Herein, we describe the glycosylation of the triterpenes from
olive fruit MA and OA by means of click chemistry to yield a
short library of synthetic mono- and bidesmosides and their
evaluation against the T-84 cell line (human colorectal
carcinoma derived from lung metastasis) and docking with
NF-κB.
■ RESULTS AND DISCUSSION
Chemistry. The cytostatic, proapoptotic, and antimetastatic
effects of saponins on tumor cells make them potential wide-
spectrum anticancer drugs.5,6 However, the degree of structural
diversity and the fact that minor structural changes in the
molecules may lead to major differences in the activity are
obstacles for the systematic study of saponins. Because the
pentacyclic triterpenes MA and OA have been proposed to
have a positive effect on colon tumors and click chemistry is a
very powerful tool in drug discovery, we envisaged the
glycosylation of MA and OA via the copper(I)-catalyzed
azide−alkyne 1,3-dipolar cycloaddition (CuAAC) as a feasible
approach to synthesizing synthetic oleanane-type triterpenoids
that may be biologically active.11−15,34,35 The rationale behind
this strategy is that besides the general benefits of click
chemistry the 1,2,3-triazole formed in CuAAC is more than a
passive linker because it can form π−π interactions with
aromatic rings and hydrogen bonds through the N(2) and
N(3) nitrogen atoms, contributing to the interaction with the
target molecule.34,35
Scheme 1. Introduction of Click Functions in MA (1) and OA (2)
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Our efforts were focused on the derivatization of the C2/C3
hydroxyl groups and the C28 carboxylic group, which
according to the literature are “active portions” of the
molecule.19 β-D-Lactose (Lac), α-D-mannose (Man), and β-
D-glucose (Glc) were linked to aglycones MA and OA to
obtain both monodesmoside- and bidesmoside-like saponins.
Commercial MA (1) and OA (2) were chemoselectively
propargylated in dimethylformamide (DMF)/K2CO3 at room
temperature for 40 h to yield the corresponding esters 3 and 4
(Scheme 1). When the propargylation of MA was carried out
Scheme 2. Structure of Clickable Azide (8−11) and Alkyne (12−14) Carbohydrates
Scheme 3. Structure of the Synthetic Oleanane-type Triterpenoids (15−29) Obtained by the Reaction of MA (1) and OA (2)
with the Clickable Carbohydrates (8−14)1
1In brackets are given the antiproliferative activities on the human colon carcinoma T-84 cell line expressed as the inhibitory concentration 50
(IC50) values resulting from the mean ± standard deviation of at least five independent measurements in the micromolar range.
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in dimethyl sulfoxide (DMSO)/NaOH, bispropargylated
compound 5 was obtained, as expected from the reported
low reactivity of the OH group at C3.19 Alternatively, an azide
group was introduced at these positions by acylation with
chloroacetic anhydride, followed by nucleophilic displacement
of the chlorine atom by azide to yield compounds 6 and 7
(Scheme 1). The counterparts clickable azide (8−11) and
alkyne (12−14) sugars derived from monosaccharides Man
and Glc, disaccharide Lac, and trivalent mannosylated dendron
(Scheme 2) were synthesized following methodologies
previously reported.36,37 Click assembly of complementary
clickable triterperne (3−7) and sugar (8−14) partners was
carried out in DMF using copper complex (EtO)3P·CuI as a
soluble catalyst and under microwave irradiation (800 W, 80
°C, 15 min) to improve the yield and reduce the reaction
time.20,38 Saponin-like compounds 15−29 were thus obtained
with good yield (Scheme 3), and their structure was confirmed
by NMR (Figures S4−S20). This short library comprises
monodesmoside- and bidesmoside-like saponins with subtle
differences derived from the aglycone (i.e., MA vs OA) as the
pairs 15−18, 16−19, or 17−20 as well as others more
divergent consequence of the increasing complexity of the
glycone (monosaccharide, disaccharide, or trivalent dendron),
its number (monodesmoside vs bisdesmoside), and its position
(ring A vs C28) (Scheme 3).
Biological Assays. Saponins commonly found in herbs and
in formulations traditionally used in Chinese medicine have
been reported to exhibit promising anticancer potential.39
Among them, the triterpenoid saponins ginsenoside Rh2 and
Rg3 and saikosaponin A show in vitro antiproliferative activity
against colon cancer cells with the inhibitory concentration 50
(IC50) ranging from 100 to 20 μM.
39 This fact led us to assay
compounds 1 (MA), 2 (OA), and 15−29 on the T-84 cell line,
a human colon carcinoma cell line derived from a lung
metastasis of colorectal carcinoma. Their antiproliferative
activity was evaluated by colorimetric quantification with
sulforhodamine B.40,41 Results are included in Scheme 3.
According to IC50, compounds can be grouped into three
categories: (i) those with an attractive IC50, including MA and
compound 18 with values of 50.2 ± 0.9 and 45.06 ± 0.6 μM,
respectively, (ii) those with IC50 within the interval 60−90 μM,
OA being at the border with IC50 89.4 ± 3.4 μM, and (iii)
those with IC50 > 90 μM and considered as inactive. This
different behavior of MA and OA has been reported in the
literature for cancer cell lines EMT-6 (breast) and SW480
(colon), and this has been explained by the additional α-
oriented hydroxyl group at C2 in MA (Scheme 3).22 The
analysis of the synthetic oleanane-type triterpenoids revels that
the modification of both hydroxyl groups of MA yielded
compounds 27−29 with low antiproliferative activity, which is
in the same order as that of compounds 24−26 obtained from
the poorly active OA aglycone. These results support the role
of the hydroxyl group at C2 of MA and suggest that the
modification of the hydroxyl group at C3 confers some
antiproliferative activity to those compounds derived from OA
(compounds 24−26) and partially compensates the effect of
the substitution at C2 of MA (compounds 27−29).
The C28 carboxyl group has been identified as one of the
“active portions” of the molecule, and amide derivatization at
C28 of β-hederin, a triterpenoid saponin whose aglycone is
OA, results in highly cytotoxic compounds.9,19 Hence, the
modification of C28 was envisaged as a synthetic approach to
converting MA and OA into more toxic synthetic oleanane-
type triterpenoids. Compounds 15−20 were synthesized, and
their biological activity was found to be dependent on both the
aglycone and the bulky nature of the substituent (Scheme 3).
Thus, compounds 15−16 derived from MA are inactive,
whereas their counterparts 18−19 from OA are active, with
IC50 of 45.6 and 65.3 μM, respectively. The steric effect of the
substituents is revealed by compounds 18−20 whose biological
activity ranges from 45.6 μM for compound 18, with a single
Man residue linked by the anomeric position, to the inactive
compound 20, bearing a trivalent dendron. In addition,
compound 19, with a Glc residue linked by C6 to test a
different orientation of the glycopyranoside ring, is less active
than compound 18. These results suggest that the modification
of C28 disturbs the interaction of MA with its target, whereas
it confers antiproliferative activity to OA by promoting either
the interaction with different targets or an alternative
interaction with the same target as MA.
Compound 18 is more active than MA despite being derived
from OA, in agreement with other authors who reported
similar results for the PEGylated OA and MA.26,27 This fact
attracted our interest, and further biological studies were
carried out. Thus, to evaluate the effect of oxidative stress on
the biological effect of compound 18, the survival rate of T-84
cells in the presence or absence of the antioxidant N-acetyl-L-
cysteine (NAC) was determined by the sulforhodamine B
colorimetric assay.42 NAC is an antioxidant frequently used as
a tool for investigating the role of the reactive oxygen species
(ROS) in biological processes.43,44 As shown in Figure 1, NAC
does not confer protection to T-84 carcinoma cells lines
treated either with compound 18, MA, or OA, discarding the
oxidative stress as the main reason responsible for the
biological action.
This result was expected because according to bibliography
MA exerts a dual activity acting as a copper chelator and a
scavenger of free radicals, whereas in vitro studies with several
breast cell lines have shown the protective effect of OA on
MCF10A cells (nontumoral cell line) by reducing the ROS
levels in the basal state.45−48 In contrast to our results, it has
been reported that NAC reverses the inhibitory effect of OA in
hepatocellular carcinoma cells, but this discrepancy can be
rationalized when considering that the authors of the study
concluded that OA triggered a new autophagic cell death
pathway in human hepatocellular carcinoma cells.49
Figure 1. Effect of NAC on the survival of the human colon
carcinoma T-84 cell line. Cells were treated with either compound 18,
OA, or MA alone (−) or in combination with 2 mM NAC (+). Values
are normalized by their control counterparts. Symbols * and **
denote a significant difference with control (−) or control (+) groups,
respectively, p < 0.05.
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Because the cell cycle machinery is one of the most
important chemotherapeutic targets, we evaluated the cell
cycle distribution of T-84 cells by flow cytometry after 24 h of
induction with three different concentrations (0.5, 1, or 2 times
the corresponding IC50 value) of compounds 18, MA, or
OA.50,51 Results are depicted in Table 1, and the representative
flow cytograms are included in the Supporting Information as
Figure S1.
The percentages of control cells (i.e., untreated) after 24 h
were 2.2% in sub-G1, 46.1% in G0−G1, 19.9% in S, and 31.8%
in G2−M. In general, the three compounds assayed provoked
an effect on the cell cycle distribution in a dose-dependent
manner to yield an increase in the sub-G1 phase and a decrease
in S and G2−M phases, although each compound showed
particular features. When cells were treated with compound 18
at a concentration of 0.5 × IC50, the cell cycle distribution
remained as that of the control cells and concentrations of 1 ×
IC50 and 2 × IC50 provoked a similar effect, yielding an
increase in G0−G1 (67%) and a decrease in S and G2−M
phases (around 4−5 and 23%, respectively), without important
changes in the sub-G1 population. MA led to appreciable
changes in the cell cycle even at 0.5 × IC50, with a dose-
dependent G0−G1 accumulation (61.8 and 73.6%, respec-
tively) and a reduction in the percentage of cells in the two
other phases. The treatment with MA at 2 × IC50 yielded an
increase of sub-G1 (12.6%) and G0−G1 (55.4%) and a
reduction in S and G2−M phases, in agreement with the
data reported for HT-29 and Caco-2 colorectal cells.12−14,52,53
Analogous to MA, OA induction also provoked changes in the
cell cycle at 0.5 × IC50, but unlike MA, the main feature of the
cell cycle was the marked dose-dependent increment of sub-
G1, from 3.1% (0.5×) to 45.8% (2×) accompanied by an initial
increment in G0−G1 at 0.5× that lowered to reach at 2× the
values of the control cell and an overall reduction of S and G2−
M phases.
These results show that MA, OA, and compound 18 are able
to inhibit G1−S phase transition. However, although the three
compounds increased the sub-G1 fraction at 24 h, the values
induced by OA are especially significant and in agreement with
the reported induction of apoptosis and inhibition of cell
proliferation.54 Interestingly, whereas OA induces a large
extent of apoptosis at a concentration 2 × IC50, the cell-cycle
profile of the cells treated with compound 18 remains almost
invariant. To confirm whether the fraction of sub-G1 cells was
due to apoptosis promotion, the viability of cells induced for
48 h with different concentrations of 18, MA, and OA was
evaluated by flow cytometry with annexin V−fluorescein
isothiocyanate (FITC) and propidium iodide (Figure 2).
The treatment with compound 18 reduced the cell viability
from 92.9% for the control group to 64.9 and 60.63% for the
cultures treated with 1 and 2 times the IC50, respectively. This
reduction of the viability was associated with an increase in the
fraction of cells in necrosis, early apoptosis, and late apoptosis,
the total apoptosis being increased from 3.8% for the control
group to 25.2 and 27.1% for the cultures treated with 1 and 2
times the IC50, respectively, revealing that both cell viability
Table 1. Effect of Compound 18, MA, and OA on the Cell Cycle of T-84 Cells after 24 h of Induction with 0.5, 1, or 2 Times
the Corresponding IC50 Value
a
treatment times IC50 sub-G1 (%) G0−G1 (%) S (%) G2−M (%)
control 2.2 ± 0.7 46.1 ± 1.4 19.9 ± 2.0 31.8 ± 3.0
compound 18 0.5× 2.2 ± 0.5 46.1 ± 2.5 20.7 ± 5.0 30.9 ± 2.3
1.0× 3.8 ± 0.4 67.6 ± 1.6* 5.6 ± 1.9* 23.0 ± 0.4*
2.0× 5.1 ± 0.2* 67.2 ± 1.3* 4.4 ± 1.2* 23.3 ± 0.7*
MA 0.5× 2.3 ± 0.1 61.8 ± 3.2* 13.2 ± 1.0* 22.6 ± 2.1*
1.0× 4.3 ± 0.7* 73.6 ± 2.2* 7.1 ± 1.9* 15.0 ± 0.9*
2.0× 12.6 ± 1.2* 55.4 ± 1.3* 6.3 ± 1.9* 25.6 ± 2.3*
OA 0.5× 3.1 ± 1.0 68.7 ± 2.9* 11.1 ± 2.0* 17.1 ± 0.5*
1.0× 19.0 ± 0.7* 54.5 ± 0.4* 3.1 ± 0.6* 23.4 ± 0.9*
2.0× 45.8 ± 0.9* 40.9 ± 5.2 8.1 ± 4.4* 5.2 ± 1.6*
aData are mean ± standard error of the mean of three independent determinations. Symbol * denotes a significant difference with the control
group, p < 0.05.
Figure 2. Effects of compound 18, MA, and OA on the viability of T-84 cells induced with 0.5, 1, or 2 times the IC50 value for 48 h. Percentages of
viable cells (VI), necrotic cells (NE), early apoptotic cells (EA-AP), late apoptotic cells (LA-AP), and total apoptotic cells (total-AP) are shown.
The experiment was repeated independently three times yielding similar results. Symbol * denotes p < 0.05 vs control cells (i.e., untreated).
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and apoptosis remain almost unaffected when the dose of
compound 18 is doubled. However, cultures treated with MA
or OA experienced a dose-dependent reduction of cell viability,
concomitant with an increment of total apoptosis that was
more accentuated with MA. MA induced 48.6 and 75% of total
apoptosis at 1× and 2×, respectively, whereas OA induced 27.3
and 40.2%, respectively. These results are in agreement with
the studies that demonstrate that MA and OA, either alone or
in combination with MA, inhibit cell proliferation, causing
apoptotic death in HT-29 cells and that OA does not lead to
apoptosis in other cell lines, such as the colon carcinoma
HCT-15, despite the success of 3-O-acetyloleanolic acid on
HCT-116.11,12,54−58
Docking Studies. Recent studies have demonstrated the
importance of chronic inflammation in colorectal cancer
development. Although the molecular mechanisms are not
fully understood, NF-κB and cyclooxygenase-2 (COX-2) have
been identified as potential therapeutic targets.29−33,59
Triterpenoids from natural sources such as ginsenosides,
glycyrrhizin, betulin, lupeol, and avicins have been identified
as inhibitors of NF-κB signaling, and this may be one of the
keys to understand their effect at cellular level.30 Additionally,
MA has been reported to suppress COX-2 expression at
concentrations that also lower the activity of NF-κB, suggesting
that the effect on NF-κB may lead to the downregulation of
different genes, including COX-2.60,61 In this context, we
hypothesized that the biological effect of MA and compound
18 might be a consequence of the interaction with NF-κB and
envisaged docking as the approach to put to test the
hypothesis.
The docking approach is not exempt of difficulty because,
despite the fact that the output results are ranked by a scoring
function, the identification of the correct solution may be far
from trivial, and for this reason, it is customary to assess the
goodness of the scoring function by redocking ligands that
have been cocrystallized with the target.62 However, to the best
of our knowledge, no structure of NF-κB bound to molecules
similar to MA has been reported and an additional difficulty is
the fact that NF-κB is a family of homo- and heterodimeric
proteins resulting from the association of five different subunits
(p50/p105 (NF-κB1), p52/p100 (NF-κB2), RelA (p65), c-Rel
(v-Rel being the viral oncogenic version), and RelB), the two
main NF-κB dimers being p50:RelA and p52:RelB hetero-
dimers.63 Hence, as a preliminary step, the binding of MA and
OA to the entire surface of p50:RelA (protein data bank
(PDB) code 1vkx) and p52:v-Rel (PDB code 3do7) was
computed. Calculations did not reach any solution for
p50:RelA, and the scoring function of the docking of MA
and OA on p52:v-Rel revealed two significant solutions for MA
and one for OA (Table 2).
The graphical analysis of the solutions revealed that MA is
predicted to bind both p52 and v-Rel, the former being the
best solution, whereas OA shares the binding mode of MA
with subunit v-Rel (Figure S2). The fact that only the
experimental antiproliferative activity of MA was significant led
us to hypothesize that binding to v-Rel was not biologically
relevant. This hypothesis was put to test by docking 6,6-
dimethyl-2-(phenylimino)-6,7-dihydrobenzo[d][1,3]oxathiol-
4(5H)-one (BOT), a newly discovered NF-κB inhibitor with
antiproliferative effect.64 The solution with the highest score
Table 2. Results of the Best Poses of the Docking of MA, OA, Compound 18, and NF-κB Inhibitor 6,6-Dimethyl-2-
(phenylimino)-6,7-dihydrobenzo[d][1,3]oxathiol-4(5H)-one (BOT) with p52:v-Rel and a Comparison with Experimental IC50
for the Human Colon Carcinoma T-84 Cell Line
compound ranka fullfitnessb binding site ΔGc estimated Kd (μM) experimental IC50 (μM)
MA 0 0 −4218.29 p52 −8.825026 0.34 50.2
1 2 −4202.93 v-Rel −6.383734 20.81
OA 0 0 −4225.85 v-Rel −6.554255 15.61 89.4
BOT 0 0 −4286.02 p52 −7.619894 2.58
18 0 0 −4156.36 p52 −9.658060 0.08 45.6
aRank resulting from the scoring function. bTotal energy of the system including solvation. cComputed ΔG of the interaction.
Figure 3. Left: poses resulting from the docking of compound 18 on p52:v-Rel (PDB accession code 3do7). Subunit v-Rel is shown in green,
subunit p52 in purple, and DNA in yellow. Right: alignment of the top score solution of MA (red) and compound 18 (cyan). The protein is shown
as a surface colored according to the hydrophobicity on the Kyte−Doolittle scale, ranging from dodger blue, for the most hydrophilic, to white and
orange red, for the most hydrophobic.
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predicted the binding of BOT to p52 in the same site as MA,
supporting the hypothesis that the binding to p52 is
biologically relevant (Figure S3).
The docking of compound 18 to the entire surface of p52:v-
Rel also predicted the binding to p52, at the same site as MA
(Figure 3).
The analysis of the interactions (Table 3) reveals that MA
and compound 18 share the hydrophobic interactions of the
triterpenic aglycone with Lys119 and Gln157 and the salt
bridge between the carboxyl group at C28 and an Arg residue.
Compound 18 also forms three additional hydrogen bonds,
one between the hydroxyl groups in position 3 of the mannose
ring and two between nitrogen atoms of the triazole ring and
Lys153, suggesting that not only the carbohydrate but also the
triazole linker plays a role in the interaction.
The Kd of the interaction was estimated from the computed
values of ΔG (Table 2). Although these estimated values may
differ considerably from the experimental dissociation
constants, they make the evaluation of the relative affinity
possible. The docking results of MA predict a lower affinity for
v-Rel than for p52, and this low affinity is shared by OA, being
consistent with the poor antiproliferative activity of OA.
Interestingly, the Kd values predicted for MA and compound
18 are 0.34 and 0.08 μM, respectively, suggesting that
compound 18 is more related to MA than to OA, as supported
by the cytometric study.
■ CONCLUSIONS
CuAAC is a suitable approach for the regioselective
modification of the C2/C3 hydroxyl and C28 carboxylic
groups of the triterpene aglycones MA and OA to yield a short
library of saponin-like compounds. The cytotoxicity assays
reveal different behaviors of OA and MA and suggest that the
modification of the hydroxyl group at C3 of these compounds
confers some antiproliferative activity to the compounds
derived from OA. The cytotoxicity of the compounds resulting
from the click modification of the C28 carboxyl group is
dependent on the aglycone and on the bulky nature of the
substituent, those derived from OA that link a monosaccharide
(Man or Glc) being active. In particular, OA bearing a Man
moiety at C28 (compound 18) is the most cytotoxic on the
human colon carcinoma T-84 cells, and it may have potential
pharmacological interest, with IC50 in the range of that
reported for ginsenoside Rh2. Biological assays show that
although compound 18 is derived from the poorly active OA
aglycone, it shares with MA the effect on the cell cycle,
inhibiting DNA replication and G1−S phase transition, and
unlike OA, it does not promote apoptosis to a large extent.
Docking experiments suggest that the biological activity may
be related to the binding to NF-κB. Both MA and compound
18 share with BOT the binding mode to the p52 subunit of
NF-κB, and the predicted affinities are in agreement with the
experimental IC50 values.
■ EXPERIMENTAL SECTION
General Chemistry Methods. All reagents and solvents
were used as obtained from commercial sources unless
otherwise indicated. All microwave reactions were performed
in a Milestone Star Microwave Labstation at 500 W. Thin-layer
chromatography (TLC) was performed on Merck Silica Gel 60
F254 aluminum sheets, and TLC plates were stained with ceric
sulfate (1% w/v) and ammonium sulfate (2.5% w/v) in 10%
Table 3. Analysis of the Interactions between p52 and MA and Compound 18a
aHB = hydrogen bond, HI = hydrophobic interaction, SB = salt bridge.
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(v/v) aqueous sulfuric acid or ethanolic sulfuric acid (10% v/
v). 1H and 13C NMR spectra were recorded at room
temperature on a Varian Direct Drive (400 or 500 MHz)
spectrometer. Chemical shifts are given in ppm and referenced
to the signal of the residual protonated solvent (1H: δ = 2.50
for DMSO-d6,
13C: δ = 39.10 for DMSO-d6). Electrospray
ionization (ESI) mass spectra were recorded with a Waters
LCT Premier XE spectrometer. Melting points were measured
with a Gallenkamp melting point apparatus and are
uncorrected. Optical rotations were recorded on a PerkinElmer
341 polarimeter at room temperature. IR spectra were
recorded with a PerkinElmer spectrum two Fourier transform
infrared attenuated total reflection spectrometer.
Synthetic Procedures. General Procedure for the
Synthesis of Mono Alkynyl Derivatives of MA and OA (3
and 4). To a solution of MA or OA (96%, 1 mmol) in DMF
(20 mL) was added propargyl bromide (80 wt % toluene, 9.3
mmol) and potassium carbonate (2.5 mmol). The obtained
suspension was stirred at room temperature for 40 h, and the
solvent was removed under vacuum. The residue was dissolved
in CH2Cl2 (30 mL) and washed successively with H2O, 5%
HCl solution, and H2O. The organic layer was dried with
anhydrous Na2SO4 and filtered, and the solvent was removed
under reduced pressure. The crude was purified by column
chromatography.
Compound 3. Column chromatography (CH2Cl2/MeOH,
20:1) yields 3 as a white solid (327 mg, 75%). The
spectroscopic data match those reported in the literature.20
Compound 4. Column chromatography (CH2Cl2/MeOH,
40:1) yields 4 as a white solid; (350 mg, 70%). The
spectroscopic data match those reported in the literature.21
Synthesis of Dialkynyl Derivative of MA (5). To a solution
of MA (96%, 825 mg, 1.68 mmol) in DMSO (8 mL) was
added propargyl bromide (80 wt % toluene, 37.2 mmol) and
NaOH (40% solution, 8 mL). The obtained suspension was
stirred at room temperature for 40 h. The resulting mixture
was diluted with Et2O/toluene 1:1 (50 mL) and washed with
H2O (3 × 25 mL). The organic layer was dried with anhydrous
Na2SO4 and filtered, and the solvent was removed under
reduced pressure. The crude was purified by column
chromatography (Et2O/hexane, 1:2), yielding 5 as a white
solid (350 mg, 70%). The spectroscopic data match those
reported in the literature.20
General Procedure for the Synthesis of Azide Derivatives
of MA and OA (6 and 7). A solution of MA or OA (96%, 1
mmol), chloroacetic anhydride (1.70 g, 10 mmol), and 4-
(dimethylamino)pyridine (196 mg, 1.6 mmol) in CH2Cl2 (20
mL) was stirred at room temperature for 16 h. The resulting
mixture was diluted with CH2Cl2 (20 mL) and washed with
H2O (25 mL). The organic layer was dried with anhydrous
Na2SO4, and the solvent was removed under vacuum to yield a
colorless syrup. The crude and NaN3 (520 mg, 8 mmol) were
dissolved in DMF (20 mL) and heated at 80 °C overnight. The
solvent was removed under reduced pressure and purified by
column chromatography.
Compound 6. Column chromatography (CH2Cl2/MeOH,
40:1) yields 6 as a white solid (543 mg, 85%); mp 169−170
°C; [α]D +14.4 (c 1, Cl3CH); IR (neat): υ̅ = 2944, 2105, 1740,
1691, 1461, 1364, 1281, 1182 cm−1; 1H NMR (500 MHz,
DMSO-d6) δ 12.0 (brs, 1H), 5.16 (brs, 1H), 5.07 (ddd, J =
11.1, 10.4, and 4.5 Hz, 1H), 4.81 (d, J = 10.4 Hz, 1H), 4.18
(s,1H), 4.05 (d, J = 17.3 Hz, 1H), 4.01 (d, J = 17.3 Hz, 1H),
2.75 (dd, J = 13.8, 3.8 Hz, 1H), 2.02−0.70 (m, 20H), 1.14 (s,
3H), 1.02 (s, 3H), 0.89 (bs, 12H), 0.73 (s, 3H); 13C NMR
(126 MHz, DMSO-d6) δ 178.54, 168.42, 168.23, 143.95,
121.09, 80.81, 70.88, 53.47, 49.49, 49.47, 46.46, 45.65, 45.42,
42.83, 41.42, 40.76, 39.15, 38.89, 37.81, 33.31, 32.82, 32.07,
31.96, 30.40, 27.92, 27.19, 25.62, 23.35, 22.96, 22.57, 17.74,
17.34, 16.75, 16.04; high-resolution mass spectrometry
(HRMS) (ESI+): m/z calcd for C34H50N6O6 [M]
+:
639.3870; found: 639.3849.
Compound 7. Column chromatography (CH2Cl2) yields 7
as a white solid (425 mg, 79%); mp 216−217 °C; [α]D +59.2
(c 1, Cl3CH); IR (neat): υ̅ = 2941, 2103, 1741, 1690, 1463,
1357, 1281, 1195 cm−1; 1H NMR (500 MHz, DMSO-d6) δ
12.0 (brs, 1H), 5.16 (t, J = 3.3 Hz, 1H), 4.52 (dd, J = 11.5 and
4.4 Hz, 1H), 4.14 (d, J = 16.9 Hz, 1H), 4.09 (d, J = 17.2 Hz,
1H), 2.74 (dd, J = 13.8 and 4.0 Hz, 1H), 1.97−1.87 (m, 1H),
1.82 (dd, J = 8.8 and 3.1 Hz, 2H), 1.71−1.20 (m, 22H), 1.11
(s, 3H), 1.10−0.96 (m, 3H), 0.90 (s, 3H), 0.87 (bs, 6H), 0.85
(s, 3H), 0.83 (s, 3H), 0.73 (s, 3H); 13C NMR (126 MHz,
DMSO-d6) δ 178.54, 168.39, 143.85, 121.37, 81.77, 54.40,
49.69, 46.79, 45.66, 45.44, 41.34, 40.79, 38.85, 37.44, 37.36,
36.46, 33.30, 32.81, 32.19, 32.07, 30.38, 27.69, 27.20, 25.56,
23.36, 23.12, 22.87, 22.60, 17.76, 16.79, 16.58, 15.16, 15.03;
HRMS (ESI−): m/z calcd for C32H48N3O4 [M − H]−:
538.3645; found: 538.3621.
General Procedure for Microwave-Assisted Click Reaction
of MA and OA with Sugars. Alkyne (3, 4, or 5) or azide (6 or
7) derivate of MA or OA (0.07−0.19 mmol) was reacted with
complementary clickable azide (8−10) and alkyne sugar (12−
14) derivatives (1.2 equiv per clickable function) in DMF (5
mL) in the presence of (EtO)3P·CuI as a soluble catalyst (0.1
equiv per clickable function) under microwave irradiation (800
W, 80 °C) for 15 min. The solvent was removed under
reduced pressure.
Compound 15. This was prepared according to the general
procedure from 3 (80 mg, 0.157 mmol) and 8 (47 mg, 0.188
mmol) and purified by column chromatography (CH2Cl2/
MeOH, 4:1) to yield a white solid (152 mg, 96%); mp 139−
141 °C; [α]D +38.4 (c 0.25, py); IR (neat): υ̅ = 3376, 2943,
1714, 1458, 1364, 1229, 1137, 1093, 1050 cm−1; 1H NMR
(500 MHz, DMSO-d6, D2O exchange) δ 7.96 (s, 1H), 5.12
(brs, 1H), 5.04 (d, J = 12.9 Hz, 1H), 5.01 (d, J = 12.9 Hz, 1H),
4.60 (d, J = 1.1 Hz, 1H), 4.56−4.43 (m, 2H), 3.90 (m, 1H),
3.82−3.66 (m, 1H), 3.56 (dd, J = 11.7 and 1.9 Hz, 1H), 3.52
(s, 1H), 3.42−3.33 (m, 5H), 3.08 (m, 1H), 2.71 (d, J = 9.4 Hz,
2H), 1.99−0.68 (several m, 20H), 1.03 (s, 3H), 0.86 (s, 3H),
0.84 (s, 3H), 0.82 (bs, 6H), 0.66 (s, 3H), 0.42 (s, 3H); 13C
NMR (101 MHz, DMSO-d6) δ 176.91, 143.64, 142.35, 125.41,
122.26, 108.96, 100.03, 82.50, 79.89, 76.94, 74.15, 70.98,
70.30, 69.67, 67.51, 66.90, 65.25, 63.50, 61.28, 57.34, 55.48,
55.09, 49.70, 47.37, 47.08, 46.43, 45.77, 41.63, 41.31, 39.21,
37.93, 33.49, 33.12, 32.62, 32.30, 30.69, 29.12, 27.38, 25.93,
23.69, 23.36, 22.85, 18.36, 17.46, 16.76, 16.64; HRMS (ESI+):
m/z calcd for C41H66N3O10 [M + H]
+: 760.4689; found:
760.4722.
Compound 16. This was prepared according to the general
procedure from 3 (100 mg, 0.196 mmol) and 10 (48 mg, 0.235
mmol) and purified by column chromatography (CH2Cl2/
MeOH, 3:1) to yield a white solid (119 mg, 85%); mp 173−
174 °C; [α]D (c 0.25, py) +67.6; IR (neat): υ̅ = 3365, 2944,
2103, 1725, 1461, 1365, 1260, 1232, 1159, 1050 cm−1; 1H
NMR (500 MHz, DMSO-d6, D2O exchange) (Glc β-anomer
55%, Glc α-anomer 45%) δ 7.90 (s, 0.45H), 7.86 (s, 0.55H),
5.13 (d, J = 3.5 Hz, 1H), 5.03 (m, 2H), 4.86 (d, J = 3.6 Hz,
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0.55H), 4.62 and 4.35 (2m, 2H), 4.24 (d, J = 7.8 Hz, 0.45H),
3.95−3.87 (m, 0.55H), 3.54−2.87 (several m, 3.45H), 1.93−
0.67 (several m, 22H), 1.02 (s, 3H), 0.87 (s, 3H), 0.84 (s, 3H),
0.82 (s, 6H), 0.66 (s, 3H), 0.41 (s, 1.65H), 0.38 (s, 1.35H);
13C NMR (151 MHz, DMSO-d6) δ 177.04, 143.74, 142.39,
142.30, 125.94, 125.90, 122.37, 97.08, 92.68, 82.59, 76.31,
74.80, 74.47, 72.87, 72.29, 71.79, 71.52, 70.14, 67.61, 57.50,
55.17, 51.40, 47.45, 47.14, 46.53, 45.84, 41.72, 41.41, 38.02,
33.56, 33.19, 32.70, 32.39, 30.76, 29.20, 27.45, 26.01, 23.77,
23.43, 22.94, 18.44, 17.54, 16.88, 16.70; HRMS (ESI+): m/z
calcd for C39H62N3O9 [M + H]
+: 716.4486; found: 716.4484.
Compound 17. This was prepared according to the general
procedure from 3 (54 mg, 0.105 mmol) and 11 (106 mg, 0.096
mmol) and purified by column chromatography (acetonitrile/
H2O, 4:1) to yield a white solid foam (114 mg, 74%); mp
121−123 °C; [α]D +26.0 (c 0.25, py); IR (neat): υ̅ = 3333,
2924, 1737, 1365, 1217, 1091, 1052 cm−1; 1H NMR (500
MHz, DMSO-d6, D2O exchange) δ 7.93 (s, 4H), 5.11 (brs,
1H), 5.03 (d, J = 12.8 Hz, 1H), 4.99 (d, J = 12.8 Hz, 1H), 4.59
(s, 3H), 4.56−4.41 (m, 8H), 4.40 (s, 6H), 3.80−3.70 (m, 6H),
3.61−3.50 (m, 6H), 3.45−3.22 (m, 22H), 3.16−3.03 (m, 4H),
2.71 (d, J = 9.3 Hz, 2H), 1.94−1.82 (m, 2H), 1.72 (m, 4H),
1.90-0.54 (several m, 20H), 1.01 (s, 3H), 0.86 (s, 3H), 0.81 (s,
3H), 0.80 (s, 3H), 0.79 (s, 3H), 0.65 (s, 3H), 0.39 (s, 3H); 13C
NMR (126 MHz, DMSO-d6) δ 177.35, 144.82, 143.93, 142.62,
125.73, 124.77, 122.51, 100.26, 82.80, 74.23, 71.18, 71.00,
70.54, 69.96, 69.71, 69.27, 69.09, 67.87, 67.10, 65.58, 64.61,
61.48, 57.60, 55.32, 50.18, 50.04, 47.61, 47.25, 46.73, 46.02,
45.57, 41.88, 41.58, 38.17, 33.74, 33.34, 32.84, 32.57, 30.91,
29.34, 27.64, 26.16, 23.92, 23.60, 23.11, 18.61, 17.68, 17.00,
16.84; HRMS (ESI+): m/z calcd for C75H122N12O2 [M + H]
+:
1622.9814; found: 1622.9813.
Compound 18. This was prepared according to the general
procedure from 4 (90 mg, 0.183 mmol) and 8 (38 mg, 0.153
mmol) and purified by column chromatography (CH2Cl2/
MeOH, 10:1) to yield a white solid (105 mg, 92%); mp 213−
214 °C; [α]D +51.6 (c 0.25, py); IR (neat): υ̅ = 3382, 2942,
1714, 1462, 1387, 1251, 1161, 1135, 1092, 1048, 1027 cm−1;
1H NMR (500 MHz, DMSO-d6, D2O exchange) δ 8.00 (s,
1H), 5.13 (brs, 1H), 5.06 (d, J = 12.7 Hz, 1H), 5.02 (d, J =
12.6 Hz, 1H), 4.78 (m, 1H), 4.60 (s, 1H), 4.52 (m, 2H), 3.91
(m, 1H), 3.76 (m, 1H), 3.51 (s, 1H), 3.40 (dd, J = 10.8 and 5.4
Hz, 1H), 3.35 (m, 2H), 3.11 (m, 1H), 2.96 (m, 1H), 2.74
(brd, J = 10.1 Hz, 1H), 1.90−0.64 (m, 22H), 1.04 (s, 3H),
0.86 (s, 3H), 0.84 (bs, 6H), 0.81 (s, 3H), 0.65 (s, 3H), 0.47 (s,
3H); 13C NMR (126 MHz, DMSO-d6) δ 176.86, 143.60,
142.35, 125.42, 122.40, 100.12, 77.27, 74.29, 71.05, 70.36,
66.98, 65.28, 61.37, 57.40, 55.22, 49.71, 47.45, 46.46, 45.81,
41.64, 41.37, 39.23, 38.76, 38.52, 36.95, 33.53, 33.16, 32.76,
32.34, 30.74, 28.63, 27.48, 27.20, 25.94, 23.75, 23.32, 22.91,
18.37, 16.81, 16.43, 15.52; HRMS (ESI+): m/z calcd for
C41H66N3O9 [M + H]
+: 744.4799; found: 744.4794.
Compound 19. This was prepared according to the general
procedure from 4 (100 mg, 0.202 mmol) and 10 (50 mg, 0.243
mmol) and purified by column chromatography (CH2Cl2/
MeOH, 5:1) to yield a white solid (118 mg, 84%); mp 170−
171 °C; [α]D +72.4 (c 0.25, py); IR (neat): υ̅ = 3387, 2942,
1726, 1463, 1388, 1361, 1253, 1159, 1048 cm−1; 1H NMR
(600 MHz, DMSO-d6, D2O exchange) (Glc β anomer 55%,
Glc α anomer 45%) δ 7.91 (s, 0.45H), 7.87 (s, 0.55H), 5.13 (d,
J = 3.6 Hz, 1H), 5.08−4.99 (m, 2H), 4.86 (d, J = 3.6 Hz,
0.55H), 4.69−4.56 (m, 1H), 4.34 (m, 1H), 4.24 (d, J = 7.8 Hz,
0.45H), 3.95−3.89 (m, 0.55H), 3.52−3.47 (m, 0.45H), 3.45 (t,
J = 9.2 Hz, 0.55H), 3.21−3.14 (m, 0.45H), 3.09 (dd, J = 9.6
and 3.6 Hz, 0.55H), 3.00−2.94 (m, 1H), 2.90 (m, 1H), 2.72
(m, 1H), 1.95−0.64 (m, 22H), 1.01 (s, 3H), 0.85 (s, 3H), 0.83
(bs, 6H), 0.62 (s, 3H), 0.80 (s, 3H), 0.45 (s, 1.65H), 0.42 (s,
1.35H); 13C NMR (151 MHz, DMSO-d6) δ 177.25, 143.77,
142.46, 126.05, 122.61, 97.15, 92.77, 77.63, 76.39, 74.89,
74.56, 72.98, 72.37, 71.85, 71.60, 70.22, 57.59, 55.39, 51.50,
47.62, 46.68, 45.97, 41.78, 41.54, 38.89, 38.68, 37.08, 33.67,
33.30, 32.91, 32.50, 30.86, 28.74, 27.61, 27.21, 26.09, 23.87,
23.46, 23.07, 18.52, 16.98, 16.93, 16.54, 15.66, 15.62; HRMS
(ESI+): m/z calcd for C39H62N3O8 [M + H]
+: 700.4537;
found: 700.4523
Compound 20. This was prepared according to the general
procedure from 4 (38 mg, 0.076 mmol) and 11 (77 mg, 0.069
mmol) and purified by column chromatography (SiO2,
acetonitrile/H2O, 5:1) to yield a white solid foam (88 mg,
80%); mp 102−104 °C; [α]D +16.2 (c 0.25, py); IR (neat): υ̅
= 3331, 2922, 1735, 1363, 1215, 1089, 1050 cm−1; 1H NMR
(500 MHz, DMSO-d6, D2O exchange) δ 7.92 (s, 3H), 7.90 (s,
1H), 5.09 (s, 1H), 5.02 (d, J = 12.9 Hz, 1H), 4.97 (d, J = 12.7
Hz, 1H), 4.59 (bs, 3H), 4.56−4.41 (m, 8H), 4.39 (s, 6H), 3.90
(m, 3H), 3.78−3.70 (m, 6H), 3.58−3.51 (m, 6H), 3.45−3.24
(m, 22H), 3.21 (s, 3H), 3.07 (m, 3H), 2.96 (m, 1H), 2.67 (m,
2H), 2.63 (m, 1H), 2.36 (m, 1H), 1.90−0.54 (several m,
20H), 0.99 (s, 3H), 0.81 (s, 3H), 0.79 (s, 3H), 0.78 (s, 3H),
0.74 (s, 3H), 0.60 (s, 3H), 0.37 (s, 3H); 13C NMR (101 MHz,
DMSO-d6) δ 177.73, 145.05, 144.03, 142.84, 125.94, 125.00,
122.81, 100.35, 78.05, 74.24, 71.30, 71.14, 70.69, 70.15, 69.39,
69.21, 67.20, 65.74, 64.71, 61.58, 57.73, 55.56, 50.39, 50.25,
47.81, 46.96, 45.72, 41.99, 41.76, 40.19, 40.15, 40.07, 39.98,
39.94, 39.77, 39.73, 39.52, 39.31, 39.10, 38.96, 38.89, 37.26,
33.87, 33.47, 32.75, 31.04, 28.90, 26.26, 24.06, 23.27, 18.71,
17.14, 16.70, 15.81; HRMS (ESI+): m/z calcd for
C75H122N12O26 [M + 2H]
2+: 803.4296; found: 803.4852.
Compound 21. This was prepared according to the general
procedure from 5 (50 mg, 0.091 mmol) and 8 (50 mg, 0.200
mmol) and purified by column chromatography (CH2Cl2/
MeOH, 4:1) to yield a white solid (80 mg, 84%); mp 132−134
°C; [α]D +24.4 (c 0.25, py); IR (neat): υ̅ = 3356, 2942, 2104,
1722, 1455, 1363, 1260, 1230, 1136, 1092, 1054 cm−1; 1H
NMR (500 MHz, DMSO-d6, D2O exchange) δ 7.97 (s, 1H),
7.96 (s, 1H), 5.12 (brs, 1H), 5.05 (d, J = 12.7 Hz, 1H), 5.01
(d, J = 12.8 Hz, 1H), 4.62−4.43 (m, 8H), 3.75 (m, 2H), 3.68−
3.50 (m, 4H), 3.46−3.29 (m, 8H), 3.06 (m, 2H), 2.87 (d, J =
9.4 Hz, 1H), 2.71 (d, J = 10.1 Hz, 1H), 1.89−0.60 (several m,
20H), 1.01 (s, 3H), 0.88 (s, 3H), 0.83 (s, 3H), 0.82 (bs, 6H),
0.69 (s, 3H), 0.40 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ
177.41, 145.65, 143.91, 142.69, 125.76, 124.78, 122.52, 100.21,
81.39, 77.18, 74.25, 74.24, 71.20, 71.15, 70.54, 67.11, 66.39,
65.57, 65.52, 62.83, 61.49, 57.55, 55.11, 50.08, 50.03, 47.60,
46.75, 46.02, 44.20, 41.90, 41.58, 38.14, 33.74, 33.38, 32.82,
32.81, 32.58, 30.94, 29.29, 27.64, 26.16, 23.94, 23.63, 23.10,
18.59, 17.77, 16.98, 16.73; HRMS (ESI+): m/z calcd for
C52H83N6O16 [M + H]
+: 1047.5850; found: 1047.5865.
Compound 22. This was prepared according to the general
procedure from 5 (70 mg, 0.127 mmol) and 10 (58 mg, 0.281
mmol) and purified by column chromatography (acetonitrile/
H2O, 7:1) to yield a white solid (99 mg, 81%); mp 174−175
°C; [α]D +24.8 (c 0.25, py); IR (neat): υ̅ = 3356, 2943, 1730,
1645, 1462, 1365, 1231, 1151, 1051 cm−1; 1H NMR (500
MHz, DMSO-d6, D2O exchange) (Glc β anomer 55%, Glc α
anomer 45%) δ 7.92, 7.89, 7.85 (3s, 2H), 5.12 (brs, 1H),
5.08−4.97 (m, 2H), 4.87 (d, J = 3.6 Hz, 1H), 4.69−4.51 (m,
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4H), 4.42−4.28 (m, 2H), 4.25 (2d, J = 7.8 Hz, 1H), 3.91 (m,
1H), 3.56−2.83 (several m, 7H), 2.70 (d, J = 11.8 Hz, 1H),
1.96−0.65 (several m, 20H), 1.00 (s, 3H), 0.87 (s, 3H), 0.82
(s, 3H), 0.80 (brs, 6H), 0.67 (brs, 3H), 0.40, 0.37 (2s, 3H);
13C NMR (126 MHz, DMSO-d6) δ 177.27, 145.26, 145.15,
143.62, 142.38, 142.30, 125.94, 125.09, 122.26, 96.84, 92.51,
92.47, 81.21, 76.96, 76.81, 76.10, 74.62, 74.37, 74.30, 72.78,
72.05, 71.62, 71.51, 71.34, 71.28, 70.11, 69.95, 62.48, 57.34,
54.84, 51.31, 47.33, 46.50, 45.73, 43.91, 41.61, 41.32, 37.85,
33.44, 33.08, 32.54, 32.30, 30.64, 28.99, 27.36, 25.89, 23.64,
23.35, 22.82, 18.33, 17.46, 16.71, 16.42; HRMS (ESI+): m/z
calcd for C48H76N6O14 [M + 2H]
2+: 480.2709; found:
480.2724.
Compound 23. This was prepared according to the general
procedure from 5 (60 mg, 0.109 mmol) and 9 (98 mg, 0.239
mmol) and purified by column chromatography (acetonitrile/
H2O, 5:1) to yield a white solid foam (109 mg, 73%); mp
186−188 °C; [α]D −6.4 (c 0.25, py); IR (neat): υ̅ = 3358,
2942, 1720, 1660, 1376, 1065 cm−1; 1H NMR (500 MHz,
DMSO-d6, D2O exchange) δ 8.04 (brs, 2H), 5.13 (brs, 1H),
5.06−4.99 (m, 2H), 4.55 (m, 6H), 4.26 (t, J = 7.2 Hz, 2H),
4.17 (brs, 2H), 4.05 (m, 2H), 3.92−3.83 (m, 2H), 3.73 (d, J =
11.4 Hz, 2H), 3.61−3.21 (m, 21H), 3.01 (m, 2H), 2.87 (d, J =
9.0 Hz, 1H), 2.71 (d, J = 12.5 Hz, 1H), 1.95−0.80 (m, 20H),
1.01 (s, 3H), 0.90 (s, 3H), 0.83 (s, 3H), 0.81 (bs, 6H), 0.68 (s,
3H), 0.41 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 177.46,
143.97, 142.63, 126.30, 125.34, 122.54, 106.95, 104.23, 104.19,
103.22, 103.15, 81.48, 80.76, 80.67, 77.24, 76.04, 75.46, 75.24,
73.57, 73.46, 71.80, 71.17, 68.77, 68.73, 68.28, 68.21, 62.86,
61.14, 61.07, 60.87, 57.66, 55.16, 50.46, 47.65, 46.80, 46.07,
44.26, 41.95, 41.64, 40.11, 40.02, 39.94, 39.86, 39.77, 39.69,
39.60, 39.52, 39.35, 39.18, 39.02, 38.18, 33.80, 33.42, 32.88,
32.60, 30.98, 29.34, 27.71, 26.24, 24.02, 23.69, 23.16, 18.66,
17.84, 17.02, 16.80; HRMS (ESI+): m/z calcd for
C64H104N6O26 [M + 2H]
2+: 686.3500; found: 686.3500.
Compound 24. This was prepared according to the general
procedure from 7 (100 mg, 0.185 mmol) and 12 (45 mg, 0.204
mmol) and purified by column chromatography (CH2Cl2/
MeOH, 5:1) to yield a white solid (130 mg, 93%); mp 258−
260 °C; [α]D +66.4 (c 0.25, py); IR (neat): υ̅ = 3375, 2943,
1743, 1693, 1463, 1366, 1270, 1214, 1134, 1055 cm−1; 1H
NMR (500 MHz, DMSO-d6, D2O exchange) δ 8.06 (s, 1H),
5.36 (d, J = 17.7 Hz, 1H), 5.27 (d, J = 17.4 Hz, 1H), 5.11 (s,
1H), 4.71 (s, 1H), 4.65 (d, J = 12.4 Hz, 1H), 4.50 (d, J = 12.4
Hz, 1H), 4.39 (s, 1H), 3.66−3.35 (m, 7H), 2.65 (m, 1H),
1.95−0.70 (several m, 22H), 1.04 (s, 3H), 0.82 (s, 9H), 0.73
(s, 3H), 0.65 (s, 3H), 0.62 (s, 3H); 13C NMR (126 MHz,
DMSO-d6) δ 167.60, 144.55, 144.31, 126.58, 122.29, 99.51,
83.28, 77.79, 74.56, 74.34, 71.36, 71.30, 70.75, 70.64, 67.42,
67.26, 61.74, 61.56, 59.51, 55.37, 54.03, 51.37, 47.68, 42.06,
38.08, 37.18, 33.98, 33.58, 32.98, 31.08, 28.40, 27.94, 26.35,
24.06, 23.66, 18.46, 17.55, 16.97, 15.71; HRMS (ESI+): m/z
calcd for C41H64N3O10 [M + H]
+: 758.4592; found: 758.459.
Compound 25. This was prepared according to the general
procedure from 7 (69 mg, 0.127 mmol) and 13 (36 mg, 0.152
mmol) after column chromatography (CH2Cl2/MeOH, 5:1)
as a white solid (79 mg, 80%); mp 245 °C (dec); [α]D +3.6 (c
0.25, py); IR (neat): υ̅ = 3363, 2943, 1742, 1692, 1463, 1366,
1271, 1216, 1034 cm−1; 1H NMR (500 MHz, DMSO-d6, D2O
exchange) δ 7.97 (s, 1H), 5.32 (d, J = 17.6 Hz, 1H), 5.23 (d, J
= 17.6 Hz, 1H), 5.10 (s, 1H), 4.40 (m, 1H), 4.23 (d, J = 9.7
Hz, 1H), 3.82 (d, J = 14.3 Hz, 1H), 3.68 (d, J = 10.7 Hz, 1H),
3.42 (dd, J = 11.9 and 6.3 Hz, 1H), 3.14 (m, 2H), 3.05 (m,
2H), 2.67 (m, 1H), 1.90−0.88 (several m, 22H), 1.03 (s, 3H),
0.82 (brs, 9H), 0.73 (s, 3H), 0.65 (s, 3H), 0.64 (s, 3H); 13C
NMR (126 MHz, DMSO-d6) δ 179.67, 167.51, 145.09, 144.47,
125.67, 122.21, 84.64, 83.04, 81.26, 78.37, 73.47, 70.57, 61.82,
55.31, 51.29, 47.64, 46.40, 46.23, 41.99, 41.49, 38.17, 38.03,
37.13, 33.96, 33.54, 32.91, 32.80, 31.02, 28.39, 27.88, 26.31,
24.01, 23.60, 23.47, 23.25, 18.44, 17.47, 17.07, 15.66; HRMS
(ESI+): m/z calcd for C41H64N3O9S [M + H]
+: 774.4363;
found: 774.4363.
Compound 26. This was prepared according to the general
procedure from 7 (76 mg, 0.140 mmol) and 14 (59 mg, 0.154
mmol) and purified by column chromatography (CH2Cl2/
MeOH, 4:1) to yield a white solid foam (120 mg, 93%); mp
261−262 °C; [α]D +8.4 (c 0.25, py); IR (neat): υ̅ = 3374,
2943, 1743, 1692, 1462, 1366, 1048 cm−1; 1H NMR (500
MHz, DMSO-d6, D2O exchange) δ 8.06 (s, 1H), 5.36 (d, 17.6
Hz, 1H), 5.27 (d, 17.6 Hz, 1H), 5.11 (s, 1H), 4.83 (d, J = 12.3
Hz, 1H), 4.65 (d, J = 12.4 Hz, 1H), 4.45−4.39 (m, 1H), 4.34−
4.28 (m, 1H), 4.19 (d, J = 6.4 Hz, 1H), 3.76−3.29 (several
multiplets, 12H), 3.08−2.99 (m, 1H), 2.72−2.59 (m, 1H),
1.86 (m, 1H), 1.77 (m, 2H), 1.65−0.85 (several m, 22H), 1.04
(s, 3H), 0.83 (s, 3H), 0.82 (bs, 6H), 0.75 (s, 3H), 0.66 (s, 3H),
0.65 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 179.93,
167.70, 144.54, 126.67, 122.28, 104.21, 102.29, 83.27, 80.70,
77.88, 76.10, 75.51, 75.41, 73.60, 71.25, 68.86, 62.10, 61.24,
60.96, 56.06, 55.32, 51.33, 47.67, 46.46, 46.35, 42.07, 41.58,
38.21, 38.12, 37.19, 33.99, 33.57, 32.97, 32.86, 31.08, 28.44,
27.92, 26.33, 24.06, 23.72, 23.65, 23.31, 18.48, 17.56, 17.08,
15.71; HRMS (ESI+): m/z calcd for C47H74N3O15 [M + H]
+:
920.5127; found: 920.5120.
Compound 27. This was prepared according to the general
procedure from 6 (100 mg, 0.156 mmol) and 12 (75 mg, 0.345
mmol) and purified by column chromatography (acetonitrile/
H2O, 5:1) to yield a white solid (140 mg, 84%); mp 139−141
°C; [α]D +26.8 (c 0.25, py); IR (neat): υ̅ = 3359, 2943, 1751,
1694, 1215, 1132, 1058 cm−1; 1H NMR (500 MHz, DMSO-d6,
D2O exchange) δ 8.09 (s, 1H), 8.05 (s, 1H), 5.42−5.24 (m,
5H), 5.09 (brs, 1H), 4.95 (brs, 1H), 4.73 (d, J = 4.5 Hz, 1H),
4.65 (d, J = 12.3 Hz, 2H), 4.50 (d, J = 12.0 Hz, 2H), 3.65−
3.35 (m, 12H), 2.74−2.61 (brs, 1H), 1.90−0.88 (several m,
20H), 1.02 (s, 3H), 0.90 (s, 3H), 0.79 (s, 3H), 0.78 (s, 3H),
0.76 (s, 3H), 0.68 (s, 3H), 0.63 (s, 3H); 13C NMR (126 MHz,
DMSO-d6) δ 180.29, 167.68, 144.63, 126.90, 126.83, 122.14,
99.90, 99.81, 82.40, 74.36, 72.57, 71.50, 70.91, 67.54, 61.85,
59.96, 59.84, 54.98, 51.36, 47.75, 46.53, 44.42, 43.82, 42.28,
41.71, 38.71, 34.28, 33.82, 33.02, 31.26, 28.87, 28.14, 26.69,
24.26, 23.93, 23.50, 18.62, 17.92, 17.61, 16.82; HRMS (ESI−):
m/z calcd for C52H77N6O18 [M − H]−: 1073.5294; found:
1073.5245.
Compound 28. This was prepared according to the general
procedure from 6 (67 mg, 0.105 mmol) and 13 (54 mg, 0.231
mmol) and purified by column chromatography (acetonitrile/
H2O, 5:1) to yield a white solid foam (94 mg, 81%); mp 146−
148 °C; [α]D −14.4 (c 0.25, py); IR (neat): υ̅ = 3351, 2944,
1748, 1695, 1462, 1353, 1267, 1214, 1039 cm−1; 1H NMR
(500 MHz, DMSO-d6, D2O exchange) δ 8.03 (s, 1H), 8.00 (s,
1H), 5.43 (d, J = 17.7 Hz, 1H), 5.32 (d, J = 17.5 Hz, 1H), 5.25
(s, 2H), 5.11 (brs, 1H), 4.97 (s, 1H), 4.69 (d, J = 10.2 Hz,
1H), 4.25 (2d, J = 10.0 Hz, 2H), 3.85 (d, J = 14.0 Hz, 2H),
3.67 (m, 2H), 3.41 (m, 2H), 3.22−3.00 (m, 8H), 2.66 (brs,
1H), 1.94−0.90 (several m, 20H), 1.07 (s, 3H), 0.98 (s, 3H),
0.92 (s, 3H), 0.82 (brs, 6H), 0.80 (s, 3H), 0.72 (s, 3H), 0.65
(bs, 3H); 13C NMR (126 MHz, DMSO-d6) δ 167.65, 167.52,
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145.24, 144.67, 125.79, 125.74, 121.87, 84.78, 84.63, 82.03,
81.25, 78.37, 73.48, 70.57, 61.81, 54.32, 51.05, 47.25, 43.39,
42.09, 38.45, 33.96, 33.52, 32.63, 31.05, 28.56, 27.85, 26.30,
24.01, 23.65, 23.56, 23.48, 18.37, 17.85, 17.47, 17.10, 16.63;
HRMS (ESI+): m/z calcd for C52H78N6O16S2 [M + H]
+:
1107.4960; found: 1107.4960.
Compound 29. This was prepared according to the general
procedure from 6 (81 mg, 0.127 mmol) and 14 (106 mg, 0.279
mmol) and purified by column chromatography (acetonitrile/
H2O, 5:1) to yield a white solid (152 mg, 86%); mp 230−231
°C; [α]D +4.0 (c 0.25, py); IR (neat): υ̅ = 3363, 2942, 1749,
1692, 1373, 1213, 1057 cm−1; 1H NMR (500 MHz, DMSO-d6,
D2O exchange) δ 8.13 (s, 1H), 8.08 (s, 1H), 5.46 (d, J = 17.6
Hz, 1H), 5.36 (d, J = 18.0 Hz, 1H), 5.27 (m, 2H), 5.10 (s,
1H), 4.98 (m, 1H), 4.84 (m, 2H), 4.66 (dd, J = 21.6 and 10.3
Hz, 4H), 4.34 (2d, J = 7.9 Hz, 2H), 4.19 (d, J = 4.5 Hz, 2H),
3.77 (d, J = 11.4 Hz, 2H), 3.60−3.31 (several m, 20H), 3.06
(brs, 2H), 2.67 (m, 1H), 1.95−0.95 (several m, 20H), 1.04 (s,
3H), 0.92 (s, 3H), 0.82 (brs, 6H), 0.80 (s, 3H), 0.73 (s, 3H),
0.65 (brs, 3H); 13C NMR (126 MHz, DMSO-d6) δ 167.36,
167.18, 144.45, 144.21, 126.36, 126.25, 121.43, 103.80, 101.99,
101.89, 81.81, 80.25, 75.70, 75.11, 75.00, 73.20, 71.93, 70.86,
68.48, 61.79, 61.69, 60.85, 60.55, 54.03, 50.71, 46.95, 41.75,
38.11, 33.21, 30.71, 28.22, 27.53, 25.96, 23.69, 23.31, 17.45,
17.15, 16.28; HRMS (ESI−): m/z calcd for C52H77N6O18 [M
− H]−: 1397.6350; found: 1397.6377.
Bioassays. Cell Lines and Culture. Human colorectal
carcinoma line T-84 was supplied by the Department of Cell
Cultures of the Granada University Scientific Instrumentation
Centre. This line was cultured at 37 °C in 5% CO2 and 90%
humidity with Dulbecco’s modified Eagle’s medium, supple-
mented with 10% heat-inactivated fetal bovine serum, 10 mL/
L penicillin−streptomycin 100×, and 2 mM L-glutamine.
Culture media and respective supplements were supplied by
Sigma-Aldrich (Madrid, Spain).
In Vitro Antiproliferative Assay. To calculate the IC50
values of the compounds, T-84 cells were seeded in 96-well
plates, and after 24 h, they were induced with increasing
concentrations of one of the compounds from 15 to 29 for 3
days. Subsequently, the cells were fixed with 10% cold
trichloroacetic acid (4 °C) and stained with 0.4% sulforhod-
amine B in 1% HOAc. The colorant was solubilized with 10
mM Tris-base, pH 10.5, and optical density values were
determined by colorimetry at 492 nm (Multiskan EX, Thermo
Electron Corporation). IC50 values were calculated from the
semilogarithmic dose−response curve by linear interpolation.
For the study of the induction of oxidative stress, cells were
treated with increasing concentrations of compounds 18, MA,
and OA in the presence or absence of 2 mM NAC for 3 days.
Then, the cultures were processed for colorimetric quantifica-
tion by the sulforhodamine B assay, as described above.
Cell Cycle Analysis. T-84 cells were seeded in six-well plates,
and after 24 h, they were induced with 0.5, 1, or 2 times the
IC50 value of 18, MA, or OA for 24 h. Then, cultures were
washed with phosphate-buffered saline (PBS), fixed with 70%
cold ethanol, and incubated with a DNA extraction solution
(0.2 M Na2HPO4, 0.1 M citric acid, pH 7.8) for 15 min at 37
°C. Cells were then centrifuged, washed with PBS, and
resuspended in 250 μL of a solution of propidium iodide (40
μg/mL) and RNAse (100 μg/mL) for 30 min at 37 °C in the
dark. Finally, samples were analyzed in a FACSCalibur (BD
Biosciences). Results were analyzed using FlowJo software (v
7.6.5, Tree Star, Inc.).
Apoptosis Assays with Annexin V. Cell viability was
determined by flow cytometry using the annexin V−FITC kit
(Pharmingen, San Diego, CA). T-84 cells were seeded in six-
well plates, and after 24 h, they were induced with 1 or 2 times
the IC50 values of 18, MA, and OA for 48 h. Cells were then
detached with PBS−ethylenediaminetetraacetate, washed twice
with cold PBS, and collected by centrifugation at 500 g for 10
min. Cells were stained following the manufacturer’s protocol,
and then samples were analyzed in a FACSCalibur (BD
Biosciences). Results were analyzed using FlowJo software (v
7.6.5, Tree Star, Inc.).
Statistical Analysis. SPSS 24 for Windows (SPSS, Chicago,
IL) was used for the statistical analysis. Results were compared
with the Student’s test, one- or two-way analyses of variance. p
< 0.05 was considered significant. Data were graphically
represented using Microsoft Excel 2010 software (Microsoft
Corporation).
Docking. Coordinate Preparation. Ghemical 2.95 was
used to generate three-dimensional coordinates of MA, OA,
BOT, and compound 18 and for geometrical minimization by
molecular mechanics with the tripos 5.2 force field until the
gradient energy was lower than 0.001 kJ/mol.65 The X-ray
coordinates of the NF-κB1 p50:p65 and NF-κB2 p52:v-Rel
complexed with DNA were extracted from the protein data
bank (PDB codes 1vkx and 3do7, respectively), and they were
prepared for docking with Dock Prep, a tool implemented in
Chimera, that deletes water molecules and ions, repairs
truncated side chains, adds hydrogens, and assigns partial
charges.66
Docking. Docking was carried out at Swiss-Dock sever in
accurate mode and without defining the region of interest
(blind docking).67 Results were clustered and ranked by their
fullfitness scores, a parameter that accounts for the total energy
of the system calculated with the CHARMM22 molecular
mechanics force field and that includes the solvation free
energy.62,68 Analysis of the results was carried out with the help
of UCSF Chimera, Poseview, and protein−ligand interaction
profiles.66,69,70 Kd values were estimated from the ΔG
computed during the docking by applying the expression ΔG
= RT ln Kd, where R is the ideal gas constant (0.0019872 kcal/
(mol K)) and T is the temperature (298 K).
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L.; Peragoń, J.; Medina, P. P.; Parra, A.; Cascante, M.; Lupiañ́ez, J. A.
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García-Salguero, L.; Mokhtari, K.; Herrera-Merchań, A.; Medina, P.
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Arańega, A.; Rodríguez-Serrano, F. Antioxidant intake and antitumor
therapy: toward nutritional recommendations for optimal results.
Oxid. Med. Cell. Longevity 2016, No. 6719534.
(45) Montilla, M. P.; Agil, A.; Navarro, M. C.; Jimeńez, M. I.;
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